Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma - PubMed

9 hours ago

Belantamab mafodotin (belamaf) combined with carfilzomib, lenalidomide, and dexamethasone (KRd-b) was evaluated for relapsed/refractory multiple myeloma (RRMM).
The study used a phase 1/2 design with belamaf administered every 8 weeks at 1.4 or 1.9 mg/kg, with 1.9 mg/kg selected as the recommended phase 2 dose.
Overall response rate was 89.5%, with 78.9% achieving very good partial response or better, and minimal residual disease negativity in all complete responders.
At a median follow-up of 19.3 months, 24-month progression-free survival and overall survival rates were 74.3% and 85.1%, respectively.
Keratopathy occurred in 94.7% of patients, mostly grade 1-2, reversible, and manageable without permanent discontinuation; grade ≥3 keratopathy was 31.6%.
Other adverse events were manageable and consistent with known profiles of KRd or belamaf.
The combination showed deep and durable responses, including in high-risk and lenalidomide maintenance dose-refractory patients.
The study supports further evaluation of KRd-b with extended-interval belamaf in phase 2 trials.

Hasty Briefsbeta